Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

iRadimed Corporation

IRMDNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Sep 25, 2026Accepted Sep 25, 2026, 4:45 PM EDTFiling CIK 1325618Accession 0001228621-26-000003
Share

Structured filing — 4

wk-form4_1790369099.xml

Open full document ↗

Filing details

Report period
2026-09-23
Issuer
IRADIMED CORP
Issuer CIK
0001325618
Trading symbol
IRMD

Reporting owner 1

Name
KIANI JOE E
Reporting owner CIK
0001228621
Relationship
Director
Address
C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO, FL, 32826

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-09-23M · Form 4698A[F1]698D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Restricted Stock Units[F1]2026-09-23M · Form 4698D0[F2][F2]Common Stock6981,397D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Footnotes

F1
Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.↩ 1↩ 2
F2
The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.↩ 1↩ 2

Signature 1

Signed
/s/ Joe E. Kiani
Date
2026-09-25

Company context

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Current securities

Recent company filings

  1. 10-Q filingOct 30, 2026
  2. Results of Operations and Financial ConditionOct 30, 2026
  3. 4 filingSep 8, 2026
  4. 144 filingSep 3, 2026
  5. Results of Operations and Financial ConditionAug 18, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.